• Species Reactivity

  Human

• Specificity

  Detects human CD109 in direct ELISAs.

• Source

  Monoclonal Mouse IgG2a Clone # 496920

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human CD109    
  Val22-Ser1268 (Tyr703Ser & Thr1241Met)    
  Accession # Q6YHK3

• Formulation

  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 750

Applications

• Recommended    
  Concentration

  Sample

• Flow Cytometry

  0.25-1 µg/10    ⁶ cells

  A431 human epithelial carcinoma cell line

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: CD109

CD109 is a GPI-anchored member of the alpha-2-macroglobulin (A2M) and complement family of proteins (1). Mature human CD109 contains a bait region with recognition sequences for multiple proteases, an internal thioester bond, and a domain similar to the receptor binding domain of A2M (2). Cleavage of A2M family proteins within the bait region activates the thioester bond to promote covalent bonding to nucleophilic groups in adjacent molecules (3, 4). Within the region included in this recombinant protein, human CD109 shares 71-73% amino acid (aa) sequence identity with mouse and rat CD109. It shares 27-33% aa sequence identity with A2M and complement factors C3, C4, and C5. Alternate splicing of human CD109 generates two isoforms with short deletions and one that is truncated within the bait region. CD109 is expressed on activated T cells and platelets, hematopoietic stem cells, megakaryocyte precursors, vascular endothelial cells, basal and myoepithelial cells of secretory glands, and squamous cell carcinomas (2, 5-9). It is produced as a 170-180 kDa glycoprotein that is autocatalytically processed to 150 kDa and 120 kDa forms (2, 6, 10). CD109 on keratinocytes binds TGF-beta and associates with TGF-beta RI and TGF-beta RII, resulting in inhibition of TGF-beta signaling (11). Polymorphisms of CD109 include the platelet-specific Gov antigen and the blood group ABH antigens (12, 13). Alloantibodies directed against these antigens result in unsuccessful platelet transfusions, neonatal alloimmune thrombocytopenia, and posttransfusion purpura (14).

• References:

1. Travis, J. and G.S. Salvesen (1983) Annu. Rev. Biochem. 52:655.

2. Lin, M. et al. (2002) Blood 99:1683.

3. Christensen, U. and L. Sottrup-Jensen (1984) Biochemistry 23:6619.

4. Wallis, R. et al. (2007) J. Biol. Chem. 282:7844.

5. Murray, L.J. et al. (1999) Exp. Hematol. 27:1282.

6. Haregewoin, A. et al. (1994) Cell. Immunol. 156:357.

7. Hasegawa, M. et al. (2007) Pathol. Int. 57:245.

8. Brashem-Stein, C. et al. (1988) J. Immunol. 140:2330.

9. Hashimoto, M. et al. (2004) Oncogene 23:3716.

10. Solomon, K.R. et al. (2004) Gene 327:171.

11. Finnson, K.W. et al. (2006) FASEB J. 20:1525.

12. Schuh, A.C. et al. (2002) Blood 99:1692.

13. Kelton, J.G. et al. (1998) J. Lab. Clin. Med. 132:142.

14. Rozman, P. (2002) Transpl. Immunol. 10:165.

• Entrez Gene IDs:

  135228 (Human); 235505 (Mouse); 363104 (Rat)

• Alternate Names:

  150 kDa TGF-beta-1-binding protein; activated T-cell marker CD109; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7; CD109 antigen (Gov platelet alloantigens); CD109 antigen; CD109 molecule; CD109; CPAMD7; CPAMD7r150; DKFZp762L1111; FLJ38569; FLJ41966; Gov platelet alloantigens; p180; Platelet-specific Gov antigen; RP11-525G3.1